Absidia Species (original) (raw)

This page updated:
1/27/2007 9:23:00 AM

DoctorFungus - All Rights Reserved© 2007 Copyright
& Privacy Policy

Site built and designed for doctorfungus by Webillustrated

Absidia spp. Berkhout, 1923 nom. cons.

| Taxonomic ClassificationKingdom: FungiPhylum: ZygomycotaSubphylum: ZygomycotinaClass: ZygomycetesOrder: MucoralesFamily: MucoraceaeGenus: _Absidia_Description and Natural Habitats Absidia spp. are filamentous fungi that are cosmopolitan and ubiquitous in nature as common environmental contaminants. They are found in plant debris and soil, as well as being isolated from foods and indoor air environment. They often cause food spoilage.SpeciesThe genus Absidia currently contains 21 species. The most commonly isolated species is Absidia corymbifera. It is the only recognized pathogen among the other Absidia species. Thus, the salient features of Absidia corymbifera only will be discussed on this page.Some of the other Absidia species are Absidia coerulea, Absidia cylindrospora, Absidia glauca, and Absidia spinosa.Synonyms for _Absidia corymbifera_[1497] Absidia ramosa _Mucor corymbifer_Pathogenicity and Clinical Significance Absidia corymbifera is a relatively rare cause of human zygomycosis. Zygomycosis is an opportunistic mycoses that manifests with pulmonary, rhinocerebral, cutaneous, gastrointestinal, renal or meningeal involvement. Disseminated zygomycosis may originate from these infections. Zygomycosis is very rarely observed in immunocompetent host [963, 1918]. Absidia corymbifera is more commonly reported as an animal pathogen. It may cause mycotic abortion in the cow [1219].Since Absidia spp. are cosmopolitan and ubiquitous in nature, they are also common laboratory contaminants. Thus, their isolation in culture requires cautious evaluation. Nevertheless, the growth of Absidia, particularly from clinical samples of patients with immunosuppression or diabetes mellitus, should be regarded as potentially significant. Also, the visualization of typical hyphae of zygomycetes group of fungi on direct microscopic examination, of particularly a sterile body site, should be considered significant even if the culture yields no growth.Macroscopic Features Absidia corymbifera grows rapidly. The rapid growing, flat, woolly to cottony, and olive gray colonies mature within 4 days. The diameter of the colony is 3-9 cm following incubation at 25°C for 7 days on potato glucose agar. The texture of the colony is typically woolly to cottony. From the surface, the colony is grey in color. The reverse side is uncolored and there is no pigment production. Absidia corymbifera is a psychrotolerant-thermophilic fungus. It grows more rapidly at 37°C than at 25°C. Its maximum growth temperature is as high as 48 to 52°C. The growth of Absidia corymbifera is optimum at 35-37°C and at a pH value of 3.0 to 8.0 [462, 1295, 2144].Microscopic FeaturesSimilar to that of the other members of the class Zygomycetes, Absidia corymbifera has wide (6-15 µm in diameter) nonseptate hyphae. A few septa may occasionally be present. Rhizoids are rarely observed. When present, the sporangiophores arise on stolons from points between the rhizoids, but not opposite the rhizoids. The sporangiophores are branched and arise in groups of 2-5 at the internodes. They often produce arches. Sporangiophores carry pyriform, relatively small (20-120 µm in diameter) sporangia. A septum is usually present just below the sporangium in the sporangiophore. The sporangiophore widens to produce the funnel-shaped apophysis beneath the sporangium. The apophysis of Absidia corymbifera is very well-developed and typical. The columella, the tip of the sporangiophore that extends into the sporangium, is semicircular in shape and has a small projection on top. Upon dissolving of the sporangial wall, a short remaining collarette may be observed overlining the apophysis. The sporangiospores are one-celled, hyaline to light black, round to oval in shape, smooth or rarely echinulate on surface and 3-4.5 µm in diameter. They are found in the sporangium and are released to the surrounding when the sporangium ruptures [462, 1295, 2144].Histopathologic FeaturesSee histopathology page for information on histopathologic appearance of zygomycetes class of fungi.Compare toThe other members of Zygomycetes; Apophysomyces, Mucor, Rhizomucor, and Rhizopus.Key Features for Differentiation from Other Members of Zygomycetes Structure Differentiation Pyriform sporangium Absidia (+); Mucor (-), Rhizomucor (-), Rhizopus (-) Septum below the sporangium Absidia (+); Apophysomyces* (-) Well-developed apophysis Absidia (+), Mucor (-), Rhizomucor (-), Rhizopus (-) Sporangiophores arising between rhizoids and not opposite them Absidia (+); Rhizopus (-) Abundant sporulation on routine mycological media Absidia (+); Apophysomyces (-) *has a dark pigmented band below the sporangiumRecent nuclear ribosomal DNA sequence data suggest that Absidia corymbifera is a sister group of _Rhizomucor miehei_-Rhizomucor pusillus. The studies on molecular phylogeny are still in progress [2341].Laboratory PrecautionsNo special precautions other than general laboratory precautions are required.SusceptibilityIn vitro susceptibility data reported so far are limited [1040, 1130]. MIC breakpoints for interpretation of in vitro susceptibility results have not been defined. Similar to the other members of the class Zygomycetes, amphotericin b appears as the sole antifungal drug which is consistently active against Absidia corymbifera . In general, it is resistant to azoles, including the newer derivatives such as voriconazole [2432]. flucytosine is also ineffective against Absidia corymbifera . Some strains may yield relatively low MICs of sordarin group of compounds. However, the significance of this finding is unclear [2212].In vivo response, on the other hand, largely depends on administration of full-dose amphotericin B therapy as well as extensive surgical debridement and correction of the underlying predisposing factors (such as immunosuppression and diabetic acidosis) [1918].For MICs of various antifungal drugs so far reported for Absidia, see our susceptibility database. | | | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | | | Search PubMedNucleotides GenBank | |

References

462. Collier, L., A. Balows, and M. Sussman. 1998. Topley & Wilson's Microbiology and Microbial Infections, 9th ed, vol. 4. Arnold, London, Sydney, Auckland, New York.

963. Hagensee, M. E., J. E. Bauwens, B. Kjos, and R. A. Bowden. 1994. Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992. Clin Infect Dis. 19:402-8.

1040. Herreros, E., C. M. Martinez, M. J. Almela, M. S. Marriott, F. G. De Las Heras, and D. Gargallo-Viola. 1998. Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi. Antimicrob. Agents Chemother. 42:2863-9.

1130. Johnson, E. M., A. Szekely, and D. W. Warnock. 1998. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 42:741-745.

1219. Knudtson, W. U., and C. A. Kirkbride. 1992. Fungi associated with bovine abortion in the northern plains states (USA). J Vet Diagn Invest. 4:181-5.

1295. Larone, D. H. 1995. Medically Important Fungi - A Guide to Identification, 3rd ed. ASM Press, Washington, D.C.

1497. McGinnis, M. R., L. Sigler, and M. G. Rinaldi. 1999. Some medically important fungi and their common synonyms and names of uncertain application. Clin Infect Dis. 29:728-30.

1918. Ribes, J. A., C. L. Vanover-Sams, and D. J. Baker. 2000. Zygomycetes in human disease. Clin Microbiol Rev. 13:236-301.

2144. St-Germain, G., and R. Summerbell. 1996. Identifying Filamentous Fungi - A Clinical Laboratory Handbook, 1st ed. Star Publishing Company, Belmont, California.

2212. Szekely, A., E. M. Johnson, and D. W. Warnock. 1999. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol. 37:1480-1483.

2341. Voigt, K., E. Cigelnik, and K. O'Donnell. 1999. Phylogeny and PCR identification of clinically important zygomycetes based on nuclear ribosomal-DNA sequence data. J Clin Microbiol. 37:3957-3964.

2432. Wildfeuer, A., H. P. Seidl, I. Paule, and A. Haberreiter. 1998. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses. 41:309-319.